Opinion|Videos|January 22, 2026
The Trial Design and Interim Results From the GCAptAIN Trial
Advertisement
Episodes in this series
This video covers the following questions:
- Secukinumab, an IL‑17A inhibitor, emerged as a promising candidate for GCA based on Phase II data from last year showing 70% sustained remission at week 28 versus 20% with placebo (
Venhoff 2023 ). - Please share the results of Phase III GCAptAIN trial. How do you interpret these findings? (
Novartis Press Release )
Advertisement
Related to this article
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.
Mirum's antibody led to virologic response and ALT normalization in up to 56% of patients at week 24, vs 0% with delayed treatment.
Murad Alam, MD, and Elizabeth Kiracofe, MD, discuss how reimbursement, coverage, and advocacy shape dermatology access for patients with skin of color.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
2
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
3
Skin of Color Savvy: Reimbursement, Coverage, and Care Gaps for Patients With Skin of Color
4
Brelovitug Meets Primary Endpoint in Phase 3 AZURE-1 Hepatitis Delta Trial
5